Clinical trials: Malaria,Falciparum
Malaria
Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine
Background: Malaria is a disease that is spread by mosquitoes. Researchers are looking for a vaccine that can prevent mosquitoes from transmitting malaria to people.
- Trial name
- NCT01867463
- Testing
- Pfs25-EPA/Alhydrogel, Euvax B, Menactra
- Where
- Mali
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Riamet® or Malarone® are both recommended as the first line treatment for uncomplicated malaria in France, according to the French consensus Conference revised in 2007 on the treatment of imported malaria.
- Trial name
- MalaRia (NCT01150344)
- Testing
- Malarone (atovaquone + proguanil combination), RIAMET (artemether + LUMEFANTRIN combination)
- Where
- France
- Volunteers
- 317 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Uncomplicated Malaria
Treatment of Uncomplicated Malaria in Benin
Malaria is a life-threatening disease especially in small children. A high degree of Plasmodium falciparum resistance to chloroquine has already spread to South-Benin where this study is taking place.
- Trial name
- NCT00460369
- Testing
- sulfadoxine-pyrimethamine, artemether-lumefantrine, amodiaquine-artesunate coformulation
- Where
- Benin
- Volunteers
- 240 people
- Sponsor
- Institut de Recherche pour le Developpement
Plasmodium Infections
Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan
In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short…
- Trial name
- NCT00330902
- Testing
- sulfadoxine-pyrimethamine (SP) plus artesunate (AS), primaquine (PQ) plus SP+AS
- Where
- Sudan
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Acute Uncomplicated Plasmodium Falciparum Malaria
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
This study was designed to determine the most effective and tolerable dose at the shortest dosing regimen of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in…
- Trial name
- NCT03167242
- Testing
- KAF156, Coartem, Lumefantrine Solid Dispersion Formulation
- Where
- 11 sites in Burkina Faso, Gabon and 7 more
- Volunteers
- 524 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger
Study treatments: Artemether-lumefantrine Artesunate-amodiaquine Dihydroartemisinin-piperaquine Location: Maradi, Niger Principal Objective: To measure the clinical and parasitological efficacy of the three artemisinin…
- Trial name
- NCT01755559
- Testing
- Artesunate-amodiaquine, Dihydroartemisinin-piperaquine, Artemether-lumefantrine
- Where
- Niger
- Volunteers
- 663 people
- Sponsor
- Epicentre
Plasmodium Falciparum, Malaria
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia
To assess the efficacy of both first-line antimalarial medications used for the treatment of uncomplicated Plasmodium falciparum malaria infections in two geographic regions in Liberia.
- Conditions
- Plasmodium Falciparum, Malaria, Uncomplicated Malaria
- Trial name
- NCT06300970
- Testing
- Amodiaquine-artesunate (ASAQ), Artemether+Lumefantrine (AL)
- Where
- 2 sites in Liberia
- Volunteers
- 352 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Plasmodium Falciparum Malaria
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria is a disease that affects many people in Africa and in Mali. It is caused by germs that are spread by mosquito bites. This study will look at the safety, effectiveness, and best dose of an experimental malaria vaccine in…
- Trial name
- NCT00349713
- Testing
- FMP2.1/AS02A, Rabies vaccine (RabAvert)
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Uncomplicated P. Falciparum Malaria in Children
Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso
Several countries in Africa have changed their first-line treatment for uncomplicated malaria to an ACT. Burkina Faso has changed its policy to Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (AQ+AS).
- Trial name
- ACTE (NCT01017770)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 4 sites in Burkina Faso
- Volunteers
- 340 people
- Sponsor
- Centre Muraz
Malaria
Immune Parameters in the Cord Blood of Newborns Exposed to Malaria in the Womb
This study, conducted by the Malaria Research and Training Center at the University of Bamako, Mali, and the NIAID, will examine how exposure to the malaria parasite in the womb affects the developing immune system of newborns.
- Trial name
- NCT00772642
- Where
- Mali
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Artemisinin Resistance in Bangladesh
A randomized, controlled clinical trial conducted in Southeastern Bangladesh using artesunate monotherapy to determine the baseline sensitivity of P. falciparum to artemisinins.
- Trial name
- NCT00639873
- Testing
- Artesunate, quinine-doxycycline
- Where
- Bangladesh
- Volunteers
- 126 people
- Sponsor
- Medical University of Vienna
Plasmodium Falciparum Infection
Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults
Single site, double-blinded, randomized, placebo-controlled clinical trial of PfSPZ-CVac safety, tolerability, immunogenicity and efficacy against naturally occurring malaria in malaria-exposed Malian adults.
- Trial name
- NCT02996695
- Testing
- Artesunate, Chloroquine, PfSPZ (NF54) Challenge
- Where
- Mali
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
Cohort Event Monitoring Study of Pyramax®
The study is to be performed in public health facilities in Central and West Africa where Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes.
- Trial name
- NCT03201770
- Testing
- pyronaridine artesunate
- Where
- 5 sites in Cameroon, Côte d’Ivoire and 3 more
- Volunteers
- 8,572 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Healthy
First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
The primary purpose of this study was to investigate the safety and tolerability of M5717 and to characterize the Pharmacokinetics (PK) /Pharmacodynamic relationship between M5717 PK and parasite clearance in healthy participants…
- Trial name
- NCT03261401
- Testing
- M5717
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Acute Uncomplicated P. Falciparum Malaria
Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers
This study will assess the safety and efficacy of co-artemether in the treatment of acute uncomplicated P. falciparum malaria in returning non-immune travellers THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
- Trial name
- NCT00233337
- Testing
- Co-artemether
- Sponsor
- Novartis Pharmaceuticals
Malaria
Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo
The Democratic Republic of the Congo (DRC) is among the countries most affected by malaria in Sub-Saharan Africa. Condidering its size and the geographic position, the DRC is meant to play a major role in the malaria control in…
- Trial name
- TETRDC2016 (NCT02940756)
- Testing
- artesunate-amodiaquine, artemether-lumefantrine, Dihydroartemisinine-piperaquine
- Where
- 6 sites in Democratic Republic of the Congo
- Volunteers
- 1,615 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Plasmodium Falciparum Malaria
Mass Vaccine and Drug Administration, Bangladesh
This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass…
- Trial name
- MVDA (NCT06068530)
- Testing
- DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™
- Where
- 2 sites in Bangladesh
- Volunteers
- 10,000 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria
Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status
The purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (SP) versus artemether-lumefantrine (Coartem) when administered to HIV+ and HIV- patients with uncomplicated P. falciparum malaria.
- Trial name
- NCT00304980
- Testing
- ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE
- Where
- Zambia
- Volunteers
- 3,000 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria
Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso
Design: Single-centre Indication: Malaria caused by Plasmodium falciparum Objectives: To determine and compare the efficacy of AQ treatment in young children with uncomplicated falciparum malaria in the rural and the urban study…
- Trial name
- NCT00261222
- Testing
- Amodiaquine
- Where
- Burkina Faso
- Volunteers
- 120 people
- Sponsor
- Heidelberg University
Malaria, Falciparum
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
- Trial name
- NCT07545681
- Testing
- GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline